{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T12:21:36Z","timestamp":1725625296757},"reference-count":20,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2023,5,31]]},"DOI":"10.5582\/irdr.2023.01009","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T22:12:59Z","timestamp":1686435179000},"page":"122-125","source":"Crossref","is-referenced-by-count":1,"title":["Autoantibodies, clinical phenotypes and quality of life in Lebanese patients with myasthenia gravis"],"prefix":"10.5582","volume":"12","author":[{"given":"Jihan","family":"Baalbaki","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Agha","sequence":"additional","affiliation":[{"name":"American University of Beirut Medical Center, Beirut, Lebanon."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisrin","family":"Jaafar","sequence":"additional","affiliation":[{"name":"American University of Beirut Medical Center, Beirut, Lebanon."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[{"name":"American University of Beirut Medical Center, Beirut, Lebanon."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Moussa","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022; 21:176-188.","DOI":"10.1016\/S1474-4422(21)00297-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: A review. Autoimmune Dis. 2012; 2012:874680.","DOI":"10.1155\/2012\/874680"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lazaridis K, Tzartos SJ. Myasthenia gravis: Autoantibody specificities and their role in MG management. Front Neurol. 2020; 11:596981.","DOI":"10.3389\/fneur.2020.596981"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Oger J, Frykman H. An update on laboratory diagnosis in myasthenia gravis. Clinica Chimica Acta. 2015; 444:126-131.","DOI":"10.1016\/j.cca.2015.01.042"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; Implications for improved diagnostics and therapeutics. Front Immunol. 2020; 11:212.","DOI":"10.3389\/fimmu.2020.00212"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Heldal AT, Eide GE, Romi F, Owe JF, Gilhus NE. Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PLoS One. 2014; 9:e114060.","DOI":"10.1371\/journal.pone.0114060"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rivner MH, Quarles BM, Pan JX, <i>et al<\/i>. Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: A multicenter study. Muscle Nerve. 2020; 62:333-343.","DOI":"10.1002\/mus.26985"},{"key":"8","unstructured":"8. Lu YR, Yu L, Ma Q, <i>et al.<\/i> Clinical characteristics and outcomes of myasthenia gravis patients with double positive antibodies against acetylcholine receptor and muscle-specific tyrosine kinase. Zhonghua Yi Xue Za Zhi. 2022; 102:942-947."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nagappa M, Mahadevan A, Gangadhar Y, Patil SA, Bokolia S, Bindu PS, Sinha S, Taly AB. Autoantibodies in acquired myasthenia gravis: Clinical phenotype and immunological correlation. Acta Neurol Scand. 2019; 139:428-437.","DOI":"10.1111\/ane.13071"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ullah U, Iftikhar S, Javed MA. Relationship between low and high anti-acetylcholine receptor antibody titers and clinical severity in myasthenia gravis. J Coll Physicians Surg Pak. 2021; 31:965-968.","DOI":"10.29271\/jcpsp.2021.08.965"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ali A, Almalki D, Kotb MA, Alenazi RS. Outcomes and characteristics of myasthenia gravis: A 10-year retrospective cross-sectional study at King Fahad Medical City. Neurosciences (Riyadh). 2022; 27:237-243.","DOI":"10.17712\/nsj.2022.4.20220038"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Masroujeh R, Otrock ZK, Yamout B, Jabbour MN, Bazarbachi A. Myasthenia gravis developing in a patient with CNS lymphoma. Int J Hematol. 2010; 91:522-524.","DOI":"10.1007\/s12185-010-0503-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. El Sayed F, Dhaybi R, Ammoury A, Chababi M, Bazex J. Myasthenia gravis with cutaneous polyarteritis nodosa. Clin Exp Dermatol. 2006; 31:215-217.","DOI":"10.1111\/j.1365-2230.2005.02015.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Antar AI, Otrock ZK, Kharfan-Dabaja MA, Mahfouz RA, Alameddine RS, El-Majzoub NM, Salem ZM. Thymoma with concomitant pure red cell aplasia, good&apos;s syndrome and myasthenia gravis responding to rituximab. Indian J Hematol Blood Transfus. 2016; 32(Suppl 1):219-222.","DOI":"10.1007\/s12288-014-0478-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Akoum R, Brihi E, Chammas S, Abigerges D. Results of radiation therapy for thymoma based on a review of 27 patients. Mol Immunol. 2003; 39:1115-1119.","DOI":"10.1016\/S0161-5890(03)00081-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Burns TM, Sadjadi R, Utsugisawa K, <i>et al<\/i>. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016; 54:1015-1022.","DOI":"10.1002\/mus.25198"},{"key":"17","unstructured":"17. Haroun-Bizri S, Maalouli J, Deeb P, Baraka A. Anesthetic management for a patient with myasthenia gravis undergoing coronary artery bypass graft. Middle East J Anaesthesiol. 2003; 17:299-305."},{"key":"18","unstructured":"18. Baraka A, Siddik S, el Rassi T, Taha S, Haroun-Bizri S. Sevoflurane anesthesia in a myasthenic patient undergoing transsternal thymectomy. Middle East J Anaesthesiol. 2000; 15:603-609."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Baraka AS, Taha SK, Kawkabani NI. Neuromuscular interaction of sevoflurane--cisatracurium in a myasthenic patient. Can J Anaesth. 2000; 47:562-565.","DOI":"10.1007\/BF03018948"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 200; 7:365-368.","DOI":"10.1038\/85520"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/12\/2\/12_2023.01009\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T04:59:29Z","timestamp":1686977969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/12\/2\/12_2023.01009\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2023.01009","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"article-number":"2023.01009"}}